Budipine
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | N04BX03 (WHO) |
| Identifiers | |
|
|
| CAS Number | 57982-78-2  |
| PubChem (CID) | 68778 |
| ChemSpider | 62021 |
| UNII | L9026OPI2Z |
| KEGG | D07306 |
| ChEMBL | CHEMBL334491 |
| ECHA InfoCard | 100.055.494 |
| Chemical and physical data | |
| Formula | C21H27N |
| Molar mass | 293.446 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (verify) | |
Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3][1]
While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[4][5] but also promoting the synthesis of dopamine.[6]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[6][7]
See also[edit]
- AD-1211
- Delucemine
- Diphenidine
- Ephenidine
- Fluorolintane
- Lanicemine
- Methoxphenidine (MXP)
- MT-45
- Remacemide
References[edit]
- ^ Martndale: The Complete Drug Reference, 35th Ed.
- ^ a b Heinz Reichmann (October 2006). "Budipine in Parkinson's tremor.". Journal of the Neurological Sciences. 248 (1-2): 53–55. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
- ^ H. Przuntek; T. Müller (1999). "Clinical efficacy of budipine in Parkinson's disease.". Journal of Neural Transmission. Supplementa. 56: 75–82. doi:10.1007/978-3-7091-6360-3_3. PMID 10370903.
- ^ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
- ^ Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.". Current Drug Targets. 2 (3): 241–271. doi:10.2174/1389450013348335. PMID 11554551.
- ^ a b Przuntek H, Bittkau S, Bliesath H, et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.
- ^ Jenny C.E. Owen; Peter S. Whitton (October 2006). "Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats.". Brain Research. 1117 (1): 206–212. doi:10.1016/j.brainres.2006.07.039. PMID 16996043.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
